image
Healthcare - Medical - Diagnostics & Research - NASDAQ - IE
$ 1.37
-7.43 %
$ 15.6 M
Market Cap
-0.51
P/E
1. INTRINSIC VALUE

Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.[ Read More ]

The intrinsic value of one TRIB stock under the base case scenario is HIDDEN Compared to the current market price of 1.37 USD, Trinity Biotech plc is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart TRIB

image
FINANCIALS
56.8 M REVENUE
-24.00%
-27 M OPERATING INCOME
-147.82%
-24 M NET INCOME
41.43%
-11.6 M OPERATING CASH FLOW
-1154.83%
24.8 M INVESTING CASH FLOW
514.19%
-16 M FINANCING CASH FLOW
-30.19%
15.8 M REVENUE
7.75%
-4.05 M OPERATING INCOME
-31.99%
-6.76 M NET INCOME
-103.71%
-3.08 M OPERATING CASH FLOW
36.14%
-3.17 M INVESTING CASH FLOW
77.32%
5.9 M FINANCING CASH FLOW
-71.72%
Balance Sheet Decomposition Trinity Biotech plc
image
Current Assets 39 M
Cash & Short-Term Investments 3.69 M
Receivables 13.4 M
Other Current Assets 22 M
Non-Current Assets 20.4 M
Long-Term Investments 214 K
PP&E 1.89 M
Other Non-Current Assets 18.3 M
Current Liabilities 15 M
Accounts Payable 3.88 M
Short-Term Debt 1.9 M
Other Current Liabilities 9.25 M
Non-Current Liabilities 68.3 M
Long-Term Debt 65.5 M
Other Non-Current Liabilities 2.83 M
EFFICIENCY
Earnings Waterfall Trinity Biotech plc
image
Revenue 56.8 M
Cost Of Revenue 37.4 M
Gross Profit 19.4 M
Operating Expenses 46.5 M
Operating Income -27 M
Other Expenses -3.03 M
Net Income -24 M
RATIOS
34.22% GROSS MARGIN
34.22%
-47.59% OPERATING MARGIN
-47.59%
-42.26% NET MARGIN
-42.26%
100.29% ROE
100.29%
-40.41% ROA
-40.41%
-87.35% ROIC
-87.35%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Trinity Biotech plc
image
Net Income -24 M
Depreciation & Amortization 1.78 M
Capital Expenditures -803 K
Stock-Based Compensation 2.07 M
Change in Working Capital -2.69 M
Others 11.4 M
Free Cash Flow -14.3 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Trinity Biotech plc
image
TRIB has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
1.1 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Trinity Biotech plc
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
20 years ago
Feb 13, 2004
Sell 3.39 M USD
ROBERT R MCCORMICK TRIBUNE FOUNDATION
10 percent owner
- 65200
52.038 USD
20 years ago
Feb 17, 2004
Sell 4.82 M USD
ROBERT R MCCORMICK TRIBUNE FOUNDATION
10 percent owner
- 92000
52.3963 USD
20 years ago
Feb 18, 2004
Sell 925 K USD
ROBERT R MCCORMICK TRIBUNE FOUNDATION
10 percent owner
- 17800
51.9396 USD
7. News
Trinity Biotech Plc (TRIB) Q3 2024 Earnings Call Transcript Trinity Biotech Plc (NASDAQ:TRIB ) Q3 2024 Earnings Conference Call November 15, 2024 10:00 AM ET Company Participants Eric Ribner - Investor Relations John Gillard – President, Chief Executive Officer Louise Tallon - Chief Financial Officer Conference Call Participants James Sidoti - Sidoti & Company Paul Nouri – Noble Equity Funds Operator Greetings. Welcome to the Trinity Biotech Third Quarter 2024 Earnings Conference Call. seekingalpha.com - 1 day ago
Trinity Biotech Announces Q3 2024 Financial Results Q3 2024 total revenue of $15.2 million grew +3% Y/Y based on strong demand and output in the TrinScreen HIV business Point-of-Care product revenue of $4.3 million grew 60% Y/Y Reiterates guidance to achieve approximately $20 million of annualized run-rate EBITDASO1 on annualized run-rate revenues of approximately $75 million by Q2 2025 Reiterates guidance to achieve 2024 sales revenue for TrinScreen HIV of approximately $10 million DUBLIN, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced the Company's results for the quarter ended September 30, 2024. Key Highlights and Developments Continued Revenue and Profitability Improvements Year-over-year revenue growth of 3% and continued disciplined execution on our profitability enhancing initiatives contributed to a decrease in the operating loss (before restructuring and impairment charges) to $2.2 million from $4.5m in Q3 2023, a 51% improvement. globenewswire.com - 1 day ago
Trinity Biotech to Announce Q3 2024 Financial Results Conference Call Scheduled for Friday, November 15, 2024 at 10:00 AM ET Conference Call Scheduled for Friday, November 15, 2024 at 10:00 AM ET globenewswire.com - 3 days ago
Trinity Biotech Regains Compliance with Nasdaq Listing Requirements DUBLIN, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq Global Select: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced that on November 6, 2024, it received written notice from the Nasdaq Stock Market LLC (“Nasdaq”) confirming that the Company has regained compliance with the minimum market value of publicly held shares (“MVPHS”) requirement under Nasdaq Listing Rule 5450(b)(2)(C) (the “MVPHS Requirement”). globenewswire.com - 1 week ago
Trinity Biotech Announces Strategic Investment in Novus Diagnostics to Advance Rapid Sepsis Testing Platform DUBLIN, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced a strategic investment in Novus Diagnostics, a company pioneering a rapid sepsis testing platform. This investment will accelerate the development and commercialization of Novus' groundbreaking point-of-care diagnostic solutions, including its 15-minute bloodstream infection test. globenewswire.com - 3 weeks ago
Trinity Biotech Enters Oncology Space with Acquisition of Prostate Cancer Focused EpiCapture DUBLIN, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced the acquisition of EpiCapture Limited, a company developing a non-invasive test for monitoring the risk of aggressive prostate cancer. This acquisition marks Trinity Biotech's strategic expansion into the oncology diagnostics market. globenewswire.com - 3 weeks ago
Trinity Biotech Shares Surge on Positive Pre-Pivotal Clinical CGM Trial TRIB announces positive results from its pre-pivotal clinical European trial for a next-gen continuous glucose monitor, setting the stage for further development in 2025. zacks.com - 1 month ago
Trinity Biotech Announces Positive Pre-Pivotal Trial Results for Its Next-Generation Continuous Glucose Monitor Technology DUBLIN, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced the successful completion of its first pre-pivotal clinical trial in Europe for its next-generation continuous glucose monitor (CGM) technology. The study assessed the analytical performance of CGM technology enhancements implemented by Trinity Biotech since acquiring the technology from Waveform Technologies in January 2024. globenewswire.com - 1 month ago
Trinity Biotech's Stock Rises After Acquisition of Metabolomics TRIB acquires Metabolomics Diagnostics, expanding its platform with cutting-edge tech to enhance diagnostics in maternal health and diabetes management. zacks.com - 1 month ago
Trinity Biotech Announces Acquisition of Metabolomics Diagnostics to Grow Presence in Maternal Health Market -Metabolomics Diagnostics, a deep-tech machine learning diagnostic platform developer, has developed an innovative test, PrePsia, to accurately predict the risk of preeclampsia in pregnant women- globenewswire.com - 1 month ago
Trinity Biotech to Initiate CGM Market Study in India in Furtherance of Intended Collaboration with Bayer DUBLIN, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today provided an update on its development and global launch plans for its next generation Continuous Glucose Monitoring (“CGM”) technology. CGMs are small patch-like wearable medical devices that use biosensor wires under the skin to measure glucose in real-time. These devices are increasingly popular in diabetes management and health monitoring. globenewswire.com - 1 month ago
Will Trinity Biotech Stock Gain From Its Latest Patent Process? TRIB announces updates on its European patented process. The company aims to use this process to improve the functionality of its glucose biosensor in its next-gen CGM technology. zacks.com - 2 months ago
8. Profile Summary

Trinity Biotech plc TRIB

image
COUNTRY IE
INDUSTRY Medical - Diagnostics & Research
MARKET CAP $ 15.6 M
Dividend Yield 0.00%
Description Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. In addition, the company sells raw materials to the life sciences industry and research institutes. It serves public health authorities, non-governmental organisations, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.
Contact IDA Business Park, Bray, A98 H5C8 https://www.trinitybiotech.com
IPO Date Oct. 21, 1992
Employees 380
Officers Mr. Colm Molloy Group Director of Human Resources & Culture Mr. John Gillard President, Chief Executive Officer, Company Secretary & Director Dr. James Walsh Ph.D. Executive Director of Business Development & Executive Director Dr. Gary Keating Ph.D. Chief Technology Officer Mr. Adrian Donohue Chief Commercial Officer Ms. Louise Tallon Chief Financial Officer & Chief Accounting Officer Ms. Jacqueline O'Neill Director of Operations Ms. Eibhlin Kelly Chief Information Officer